Nature Medicine, Published online: 31 March 2026; doi:10.1038/d41591-026-00018-2
In the phase 3 EVOKE(+) trials, semaglutide did not slow clinical progression of Alzheimer’s disease, but the findings provide new insights in the ongoing quest for treatments.
